183 related articles for article (PubMed ID: 19419940)
1. Mutations of the KRAS oncogene in endometrial hyperplasia and carcinoma.
Dobrzycka B; Terlikowski SJ; Mazurek A; Kowalczuk O; Niklińska W; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2009; 47(1):65-8. PubMed ID: 19419940
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations.
Hong W; Abi-Raad R; Alomari AK; Hui P; Buza N
Hum Pathol; 2015 Jul; 46(7):1000-5. PubMed ID: 25997988
[TBL] [Abstract][Full Text] [Related]
3. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
[TBL] [Abstract][Full Text] [Related]
6. Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.
Zauber P; Denehy TR; Taylor RR; Ongcapin EH; Marotta S; Sabbath-Solitare M
Int J Gynecol Cancer; 2015 Jun; 25(5):863-8. PubMed ID: 25768080
[TBL] [Abstract][Full Text] [Related]
7. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia.
Sun H; Enomoto T; Fujita M; Wada H; Yoshino K; Ozaki K; Nakamura T; Murata Y
Am J Clin Pathol; 2001 Jan; 115(1):32-8. PubMed ID: 11190805
[TBL] [Abstract][Full Text] [Related]
8. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
9. [KRAS mutations analysis in mucinous epithelial lesions of the endometrium].
Zheng XZ; Zhan Y; Ma JH; Xu HW; Zhi WX; Chen TB; Qin XY; Wang P; Zhang LH; Gu YC; Jin YL; Zhu L; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):687-690. PubMed ID: 30220122
[No Abstract] [Full Text] [Related]
10. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
12. ras gene mutations in human endometrial carcinoma.
Varras MN; Koffa M; Koumantakis E; Ergazaki M; Protopapa E; Michalas S; Spandidos DA
Oncology; 1996; 53(6):505-10. PubMed ID: 8960147
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiles of benign and (pre)malignant endometrial lesions.
van der Putten LJM; van Hoof R; Tops BBJ; Snijders MPLM; van den Berg-van Erp SH; van der Wurff AAM; Bulten J; Pijnenborg JMA; Massuger LFAG
Carcinogenesis; 2017 Mar; 38(3):329-335. PubMed ID: 28203752
[TBL] [Abstract][Full Text] [Related]
14. Frequent KRAS mutation in complex mucinous epithelial lesions of the endometrium.
Alomari A; Abi-Raad R; Buza N; Hui P
Mod Pathol; 2014 May; 27(5):675-80. PubMed ID: 24186144
[TBL] [Abstract][Full Text] [Related]
15. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB
Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803
[TBL] [Abstract][Full Text] [Related]
16. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.
Sasaki H; Nishii H; Takahashi H; Tada A; Furusato M; Terashima Y; Siegal GP; Parker SL; Kohler MF; Berchuck A
Cancer Res; 1993 Apr; 53(8):1906-10. PubMed ID: 8467512
[TBL] [Abstract][Full Text] [Related]
17. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
[TBL] [Abstract][Full Text] [Related]
18. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma.
Guerra F; Kurelac I; Cormio A; Zuntini R; Amato LB; Ceccarelli C; Santini D; Cormio G; Fracasso F; Selvaggi L; Resta L; Attimonelli M; Gadaleta MN; Gasparre G
Hum Mol Genet; 2011 Jun; 20(12):2394-405. PubMed ID: 21470976
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
Stewart CJ; Amanuel B; Grieu F; Carrello A; Iacopetta B
J Clin Pathol; 2010 Jul; 63(7):604-8. PubMed ID: 20591910
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
